Marshall Wace
KALV

Marshall Wace’s KalVista Pharmaceuticals KALV Stock Holding History

Marshall Wace’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.28M Buy
+162,908
New +$2.63M ﹤0.01% 1525
2025
Q4 		– Sell
-370,773
Closed -$4.52M – 3209
2025
Q3 		$4.52M Buy
370,773
+251,151
+210% +$3.47M ﹤0.01% 1222
2025
Q2 		$1.35M Buy
119,622
+38,657
+48% +$473K ﹤0.01% 1728
2025
Q1 		$934K Sell
80,965
-37,013
-31% -$378K ﹤0.01% 1813
2024
Q4 		$999K Buy
117,978
+103,072
+691% +$1.07M ﹤0.01% 1739
2024
Q3 		$173K Sell
14,906
-34,005
-70% -$428K ﹤0.01% 2312
2024
Q2 		$576K Sell
48,911
-579,976
-92% -$6.77M ﹤0.01% 1910
2024
Q1 		$7.46M Buy
+628,887
New +$8.38M 0.01% 851
2023
Q4 		– Sell
-51,524
Closed -$496K – 2400
2023
Q3 		$496K Buy
+51,524
New +$526K ﹤0.01% 1733
2023
Q1 		– Sell
-18,396
Closed -$124K – 2889
2022
Q4 		$124K Buy
+18,396
New +$98.5K ﹤0.01% 2769
2022
Q3 		– Sell
-133,687
Closed -$1.32M – 3569
2022
Q2 		$1.32M Buy
133,687
+97,328
+268% +$1.07M ﹤0.01% 2276
2022
Q1 		$536K Buy
+36,359
New +$522K ﹤0.01% 2746
2021
Q3 		– Sell
-16,996
Closed -$407K – 3234
2021
Q2 		$407K Sell
16,996
-20,447
-55% -$535K ﹤0.01% 2224
2021
Q1 		$962K Buy
+37,443
New +$984K ﹤0.01% 1689
2020
Q2 		– Sell
-18,454
Closed -$141K – 1767
2020
Q1 		$141K Buy
+18,454
New +$249K ﹤0.01% 1260
2019
Q2 		– Sell
-29,452
Closed -$843K – 1597
2019
Q1 		$843K Buy
+29,452
New +$638K 0.01% 990

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace's KALV Position: Q1 2026 in Review

Marshall Wace opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 162,908 shares worth $3.28M. The stake represents ﹤0.01% of the portfolio and ranks #1525 among its holdings. This is a return to the name: Marshall Wace previously reported a position in KALV as recently as Q3 2025.

Marshall Wace first reported a position in KALV in Q1 2019 and has held it in 16 quarters since. The position peaked at $7.46M in Q1 2024. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Marshall Wace held 162,908 shares of KalVista Pharmaceuticals worth $3.28M as of Q1 2026.
  • KalVista Pharmaceuticals was a new Marshall Wace position in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1525 holding.
  • Marshall Wace first reported a position in KalVista Pharmaceuticals in Q1 2019 and has held it in 16 quarters since.
  • Marshall Wace's KalVista Pharmaceuticals position peaked at $7.46M in Q1 2024.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.